Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome
Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and
Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects
with Typical Werner Syndrome.
There will be up to 5 subjects that will receive treatment with Progerinin twice daily for
approximately 1 year.